)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cadrenal Therapeutics
Cadrenal Therapeutics (CVKD) investor relations material
Cadrenal Therapeutics AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary24 Sep, 2026
Opening remarks and agenda
Meeting called to order by the CEO, with board members, management, legal counsel, and auditors present virtually.
The agenda included five business items, with voting instructions and Q&A procedures explained.
Board and executive committee updates
The board is divided into three classes, with the Class I director's term expiring at this meeting.
Quang X. Pham was nominated for re-election as Class I director for a three-year term.
Shareholder proposals
Election of one director for a three-year term.
Ratification of the independent registered public accounting firm for 2026.
Approval of an amendment to the 2022 Successor Equity Incentive Plan to increase available shares.
Approval of issuance of up to 960,000 shares upon exercise of Series C-1 warrants.
Approval of potential adjournment to solicit further votes if needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cadrenal Therapeutics
- Late-stage pipeline with orphan designations targets $3B+ cardiac and rare disease markets.CVKD
Investor presentation - Net loss improved and clinical advances made, but more funding is needed for future trials.CVKDQ2 2026
- Annual meeting seeks approval for director, auditor, equity plan, and new share issuance.CVKDProxy filing
- Stockholders will vote on director election, auditor ratification, equity plan, and warrant issuance.CVKDProxy filing
- Stockholders will vote on director election, auditor ratification, equity plan, and warrant issuance.CVKDProxy filing
- Registering 2.94M shares for resale from PIPE warrants, with high dilution and capital risk.CVKDRegistration filing
- CAD-1005 offers a novel, upstream approach to HIT, aiming to improve outcomes and reduce costs.CVKDLytham Partners Spring 2026 Investor Conference
- First-in-class 12-LOX inhibitor CAD-1005 targets HIT, aiming for $1B+ market with Phase 3 in 2027.CVKDInvestor presentation
- Net loss narrowed and cash runway extended by $2.5M financing, enabling Phase 3 trial advancement.CVKDQ1 2026
Next Cadrenal Therapeutics earnings date
Q3 202620 Nov, 2026
Cadrenal Therapeutics
Next Cadrenal Therapeutics earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development of tecarfarin, an advanced oral anticoagulant. Tecarfarin is designed to prevent heart attacks, strokes, and deaths caused by blood clots, particularly in patients with rare cardiovascular conditions that require long-term anticoagulation therapy. These conditions include end-stage kidney disease (ESKD), atrial fibrillation, and complications related to left ventricular assist devices (LVADs). The company aims to address the limitations of existing anticoagulants like warfarin, offering a more stable and reliable treatment option through an alternative metabolic pathway. The company is headquartered in Ponte Vedra, Florida, and its shares are listed on the NASDAQ.